Could a diabetes drug before bariatric surgery supercharge weight loss?

NCT ID NCT07622992

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will compare three approaches before gastric bypass surgery for severe obesity: taking the medication tirzepatide for 60 days, following a ketogenic diet for 4 weeks, or receiving standard care. The goal is to see which method leads to the most weight loss one year after surgery. The trial will also track safety and improvements in related health issues like diabetes and high blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tirzepatide
What this could lead to
If successful, this could show that a short course of tirzepatide before surgery leads to greater weight loss and better control of obesity-related conditions like diabetes and high blood pressure.
What could go wrong
This is a small, early-stage study with only 96 participants, so results may not apply to everyone. The benefits of tirzepatide may not persist long-term, and the drug can cause side effects like nausea or vomiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Federico II of Naples

    Naples, Italy, 80131, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.